Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk files another Lantus rival in Japan

Danish pharma company's combination product - known as DegludecPlus in Europe – submitted to regulators

Novo Nordisk has filed for approval of its combination product based on insulin degludec and insulin aspart in Japan as it continues its assault on the ultra-long-acting insulin market.

The combination product - referred to as DegludecPlus in Europe - is part of a franchise that Novo Nordisk is positioning to challenge the dominance of Sanofi's Lantus (insulin glargine) in the diabetes category. Lantus brought in sales of€3.92bn ($5.2bn) last year and is the world's top-selling insulin product.

The combination product combines insulin degludec - a new ultra-long-acting insulin analogue that is currently under regulatory review in Europe, the US and Japan - with Novo Nordisk's fast-acting NovoRapid product, which had revenues of 12.8 billion krone ($2.3bn) last year.

One of the advantages of insulin degludec is that it can be administered at any time of day to fit in with the needs of the patient, and that flexibility has led to speculation that in time it could overtake Lantus and become the top insulin product worldwide with multibillion dollar sales.

Novo Nordisk launched another long-acting insulin called Levemir a few years ago but this has not been able to match Lantus' growth trajectory.

The Japanese marketing application is based on results of the BOOST clinical programme, which involved nearly 3,000 type 1 and type 2 diabetes patients and showed improved blood glucose control compared to Lantus, as well as reductions in the rate of hypoglycaemia episode during the night compared to biphasic insulin aspart.

Novo Nordisk is planning to develop a series of combination products based on insulin degludec. Last year, it started phase III trials of a combination product based on insulin degludec and GLP-1 analogue liraglutide - the active ingredient in its Victoza product.

The pharma company is claiming to be further ahead with this programme than a Sanofi follow-up to Lantus which combines insulin glargine with GLP-1 analogue lixisenatide, which will be marketed as Lyxumia if it is approved.

9th March 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Spoonful of Sugar

Spoonful of Sugar (SoS) is a unique and diverse team of specialists in illness and medicines-related behaviour, hand-picked from academic,...

Latest intelligence

Online Physician Communities
M3 improves personalisation of pharma engagement with doctors
Launches new messaging service on Doctors.net.uk...
Digital Futures 2014 slide deck
Full slides, including survey data, from PMLiVE's digital pharma marketing online event...
The Chinese diabetes challenge
Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential ...